Lori Kunkel

Dr. Kunkel has served as a member of the board of directors since June 2020. She currently serves on the board of directors of Nurix Therapeutics, K36 Therapeutics, and Curis, and has served on the board of directors of Maverick Therapeutics, Loxo Oncology, Amphivena, Harpoon Therapeutics and Tocagen. Dr. Kunkel has been a principal and owner of LAK505, LLC, a biotech consulting company, since 2016. Previously, she served as acting Chief Medical Officer at Loxo Oncology, as Chief Medical Officer at Pharmacyclics and Proteolix, and in various senior clinical roles at Baxter Healthcare, Chiron, and Genentech. Prior to joining the biotechnology industry in 1995, Dr. Kunkel spent ten years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at the University of California, Los Angeles. Dr. Kunkel received her M.D. from University of Southern California and her B.S. in biology from University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology.